
|Videos|April 26, 2022
Updates from Bausch and Lomb: US launch of FDA approved treatment for uveitis, new IOL toric calculator
Author(s)Kassi Filkins
Chuck Hess, vice president and general manager, Bausch and Lomb, discusses XIPERE™, the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, and other new things rolled out recently from the company.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Eli Lilly to acquire Adverum Biotechnologies
2
Regeneron receives another CRL for its Eylea 8 mg
3
Anti-VEGF innovations in retinal disease: From molecules to medicine
4
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa
5


















































.png)


